Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of wAMD.~* Patients for whom the decision to initiate treatment with IVT aflibercept in a proactive regimen was made as routine clinical practice.~* Treatment-naïve in the study eye (no prior therapy for wAMD).~* Patient age ≥50 years of age.~* Written informed patient consent before the start of data collection (according to the requirements of the local authorities and laws).~Exclusion Criteria:~* Participation in an investigational program with interventions outside of routine clinical practice.~* Patients with contraindications to IVT aflibercept listed in the local marketing authorization.~* Planned treatment regimen outside of the local marketing authorization.~* Patients with eye diseases, e.g. advanced glaucoma or visually significant cataracts, likely to require surgery during the observation period in the study eye.~* Concomitant ocular or systemic administration of drugs up to 3 months before IVT aflibercept treatment that could interfere with or potentiate the mechanism of action of IVT aflibercept, including other anti-VEGF agents in the fellow eye.~* Any other retinal disease which may interfere with the treatment of wAMD.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- wAMD patients (Type: None): Patients with a diagnosis of wAMD and naïve to any treatment in the study eye will be enrolled after the decision by treating physician for IVT aflibercept therapy according to the local label.

Based on this trial design, predict the completion outcome and termination type (if applicable).